[1] |
Gonzalez⁃Santiago TM, Davis MD. Update of management of connective tissue diseases: livedoid vasculopathy[J]. Dermatol Ther, 2012, 25(1529⁃8019 (Electronic): 183⁃194.
|
[2] |
Criado PR, Rivitti Ea Fau Sotto MN, Sotto Mn Fau Valente NYS, et al. Livedoid vasculopathy: an intringuing cutaneous disease[J]. Anais Brasileiros de Dermatologia, 2011, 86(1806⁃4841 (Electronic): 961⁃977.
|
[3] |
Browning CE, Callen JP. Warfarin therapy for livedoid vasculopathy associated with cryofibrinogenemia and hyperhomocysteinemia[J]. Arch Dermatol, 2006, 142(0003⁃987X (Print): 75⁃78.
|
[4] |
Di Giacomo TB, Hussein Tp Fau Souza DG, Souza Dg Fau Criado PR, et al. Frequency of thrombophilia determinant factors in patients with livedoid vasculopathy and treatment with anticoagulant drugs: a prospective study[J]. J Eur Acad Dermatol Venereol, 2010, 24(1468⁃3083 (Electronic): 1340⁃1346.
|
[5] |
Khenifer S, Thomas L, Balme B, et al. Livedoid vasculopathy: thrombotic or inflammatory disease?[J]. Clin Exp Dermatol, 2010, 35(7): 693⁃698. DOI: 10.1111/j.1365⁃2230.2009.03732.x.
|
[6] |
Khenifer S, Thomas L, Balme B, et al. Livedoid vasculiltis associated with a double heterozygous Factor V Leiden and prothrombin G20210A gene mutations[J]. Clin Exp Dermatol, 2009, 34(8): e811⁃e813. DOI: 10.1111/j.1365⁃2230.2009.03541.x.
|
[7] |
袁建国, 蔡在胜, 刘睿, 等. 47例青斑血管炎临床分析[J]. 中华皮肤科杂志, 2013, 46(9): 630⁃632. DOI: 10.3760/cma.j.issn.0412⁃4030.2013.09.006.
|
|
Yuan JG, Cai ZS, Liu R, et al. Clinical analysis of 47 cases of livdo vasculits[J]. Chin J Dermatol, 2013, 46(9): 630⁃632. DOI: 10.3760/cma.j.issn.0412⁃4030.2013.09.006.
|
[8] |
Feng SY, Jin PY, Shao CG. The significance of anticardiolipin antibody and immunologic abnormality in livedoid vasculitis[J]. Int J Dermatol, 2011, 50(1): 21⁃23. DOI: 10.1111/j.1365⁃4632.2010.04569.x.
|
[9] |
McCalmont CS, McCalmont TH, Jorizzo JL, et al. Livedo vasculitis: vasculitis or thrombotic vasculopathy?[J]. Clin Exp Dermatol, 1992, 17(1): 4⁃8.
|
[10] |
Criado PR, Rivitti EA, Sotto MN, et al. Livedoid vasculopathy as a coagulation disorder[J]. Autoimmun Rev, 2011, 10(6): 353⁃360. DOI: 10.1016/j.autrev.2010.11.008.
|
[11] |
Yong AA, Tan AW, Giam YC, et al. Livedoid vasculopathy and its association with factor V Leiden mutation[J]. Singapore Med J, 2012, 53(12): e258⁃e260.
|
[12] |
Boyvat A, Kundakci N, Babikir MO, et al. Livedoid vasculopathy associated with heterozygous protein C deficiency[J]. Br J Dermatol, 2000, 143(4): 840⁃842.
|
[13] |
Baccard M, Vignon⁃Pennamen MD, Janier M, et al. Livedo vasculitis with protein C system deficiency[J]. Arch Dermatol, 1992, 128(10): 1410⁃1411.
|
[14] |
Hairston BR, Davis MD, Pittelkow MR, et al. Livedoid vasculo⁃pathy: further evidence for procoagulant pathogenesis[J]. Arch Dermatol, 2006, 142(11): 1413⁃1418. DOI: 10.1001/archderm.142.11.1413.
|
[15] |
Agirbasli M, Eren M, Eren F, et al. Enhanced functional stability of plasminogen activator inhibitor⁃1 in patients with livedoid vasculopathy[J]. J Thromb Thrombolysis, 2011, 32(1): 59⁃63. DOI: 10.1007/s11239⁃011⁃0556⁃y.
|
[16] |
Castillo⁃Martinez C, Moncada B, Valdes⁃Rodriguez R, et al. Livedoid vasculopathy (LV) associated with sticky platelets syndrome type 3 (SPS type 3) and enhanced activity of plasmi⁃nogen activator inhibitor (PAI⁃1) anomalies[J]. Int J Dermatol, 2014, 53(12): 1495⁃1497. DOI: 10.1111/j.1365⁃4632.2012. 05786.x.
|
[17] |
Acland KM, Darvay A, Wakelin SH, et al. Livedoid vasculitis: a manifestation of the antiphospholipid syndrome?[J]. Br J Dermatol, 1999, 140(1): 131⁃135.
|
[18] |
Chen KR, Toyohara A, Suzuki A, et al. Clinical and histo⁃pathological spectrum of cutaneous vasculitis in rheumatoid arthritis[J]. Br J Dermatol, 2002, 147(5): 905⁃913.
|
[19] |
Klein KL, Pittelkow MR. Tissue plasminogen activator for treatment of livedoid vasculitis[J]. Mayo Clin Proc, 1992, 67(10): 923⁃933.
|
[20] |
梁晶, 宋泽蓉, 李红艳, 等. 白色萎缩6例误诊分析[J]. 实用医学杂志, 2012(12): 2083⁃2084. DOI: 10.3969/j.issn.1006⁃5725. 2012.12.060.
|
|
Liang J, Song ZR, Li HY, et al. Analysis of six misdiagnosed cases of white atrophy[J]. J Pract Med, 2012(12): 2083⁃2084. DOI: 10.3969/j.issn.1006⁃5725.2012.12.060.
|
[21] |
Callen JP. Livedoid vasculopathy: what it is and how the patient should be evaluated and treated[J]. Arch Dermatol, 2006, 142(11):1481⁃1482. DOI: 10.1001/archderm.142.11.1481.
|
[22] |
Criado PR, de Souza Espinel ID, Valentef NS, et al. Livedoid vasculopathy and high levels of lipoprotein (a): response to danazol[J]. Dermatol Ther, 2015, 28(4): 248⁃253. DOI: 10.1111/dth.12225.
|
[23] |
Kerk N, Drabik A, Luger TA, et al. Rivaroxaban prevents painful cutaneous infarctions in livedoid vasculopathy[J]. Br J Dermatol, 2013, 168(4): 898⁃899. DOI: 10.1111/bjd.12100.
|
[24] |
Mofarrah R, Aberer W, Aberer E. Treatment of livedoid vasculo⁃pathy with alprostadil (PGE⁃1): case report and review of published literature[J]. J Eur Acad Dermatol Venereol, 2013, 27(2): e252⁃e254. DOI: 10.1111/j.1468⁃3083.2012.04480.x.
|